iNova Pharmaceuticals Pty. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From iNova Pharmaceuticals Pty. Ltd.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Asia Executives On The Move: Returners And Leavers At Merck; Changes At Takeda, Ono, Simcere And More
Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director for commercial health. Top executives change also take place at Ono in Korea and Simcere Pharma.
The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.
At first glance, giving back Addyi to the original owners for next to nothing looks like a complete disaster but investors are relieved debt-ridden Valeant has managed to offload another asset.
- OTC, Consumer
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.